Jeremiah Malerich, Ph.D., is a medicinal chemist, who focuses on designing and synthesizing new small molecules to cure disease. A major thrust of his current research is teaming with SRI’s Immunology group in the discovery of selective kinase inhibitors for use against autoimmune diseases such as arthritis and sepsis. He also collaborates with the Bioinformatic Research Group to extend the value of MetaCyc, a database of metabolic pathways maintained at SRI. 

In his academic studies, he became an adept and versatile synthetic organic chemist with particular success in biomimetic synthesis and catalysis. Malerich received his B.S. in chemistry from the University of Notre Dame. He completed a Ph.D. in chemistry from the University of California, Berkeley, and went on to postdoctoral research at the University of Chicago before joining SRI.

View Dr. Malerich’s publications on PubMed.